Michael Crowley - 09 Aug 2021 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role: EVP, GBL Commercial Operations
Signature: /s/ Michael Crowley
Issuer symbol: BIO
Transactions as of: 09 Aug 2021
Net transactions value: -$1,846,116
Form type: 4
Filing time: 10 Aug 2021, 11:58:29 UTC
Next filing: 03 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIO	Bio-Rad A Common Stock	Options Exercise	$418,680	+3,000	+82%	$139.56	6,669	09 Aug 2021	Direct
transaction	BIO	Bio-Rad A Common Stock	Sale	$1,939,836	-2,570	-39%	$754.80	4,099	09 Aug 2021	Direct	F1
transaction	BIO	Bio-Rad A Common Stock	Sale	$324,960	-430	-10%	$755.72	3,669	09 Aug 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIO	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3,000	-100%	$0.000000^*	0	09 Aug 2021	Bio-Rad A Common Stock	3,000	$139.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $754.52 to $755.39, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $755.52 to $756.30, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 11, 2016, which was the first anniversary of the date on which the option was granted.